JR
Highly rated in
6
conditions
Highly rated in
6
conditions
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Julio Rosenstock's experience treating your condition:
About Dr. Julio Rosenstock

Julio Rosenstock is an Endocrinologist in Dallas, Texas. Rosenstock has been practicing medicine for over 48 years and is highly rated in 6 conditions, according to our data. His top areas of expertise are Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Low Blood Sugar, and Obesity. He is licensed to treat patients in Texas.

His clinical research consists of co-authoring 263 peer reviewed articles and participating in 30 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Julio Rosenstock it is best to call his office and ask if your insurance is accepted.


Call to see if your plan is accepted.
Locations
7777 Forest Ln, C685, Dallas, TX 75230
Background & Education
Graduate Institution
Other, 1975
Specialties
Endocrinology
Licenses
Internal Medicine in TX
Hospital Affiliations
Medical City Dallas
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


30 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of LY3298176 Versus Placebo in Patients With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
View 24 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors